La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Charmacy Pharmaceutical Résultats passés
Passé contrôle des critères 2/6
Charmacy Pharmaceutical has been growing earnings at an average annual rate of 15.6%, while the Healthcare industry saw earnings growing at 6.9% annually. Revenues have been growing at an average rate of 3.9% per year. Charmacy Pharmaceutical's return on equity is 8.6%, and it has net margins of 1.2%.
Informations clés
15.6%
Taux de croissance des bénéfices
15.6%
Taux de croissance du BPA
| Healthcare Croissance de l'industrie | 11.3% |
| Taux de croissance des recettes | 3.9% |
| Rendement des fonds propres | 8.6% |
| Marge nette | 1.2% |
| Prochaine mise à jour des résultats | 28 Aug 2024 |
Mises à jour récentes des performances passées
Recent updates
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased
May 13
There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump
Apr 24Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 19These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well
Oct 25If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity
Sep 17Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?
May 02What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Mar 15Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?
Feb 17We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide
Jan 27Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture
Jan 09What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us
Dec 22
Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years
Nov 29Ventilation des recettes et des dépenses
Comment Charmacy Pharmaceutical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Dec 23 | 4,404 | 51 | 171 | 0 |
| 30 Sep 23 | 4,480 | 74 | 173 | 0 |
| 30 Jun 23 | 4,557 | 96 | 175 | 0 |
| 31 Mar 23 | 4,366 | 93 | 170 | 0 |
| 31 Dec 22 | 4,175 | 90 | 165 | 0 |
| 30 Sep 22 | 3,931 | 54 | 159 | 0 |
| 30 Jun 22 | 3,688 | 18 | 153 | 0 |
| 31 Mar 22 | 3,741 | 20 | 152 | 0 |
| 31 Dec 21 | 3,794 | 23 | 152 | 0 |
| 30 Sep 21 | 3,959 | 29 | 153 | 0 |
| 30 Jun 21 | 4,124 | 36 | 154 | 0 |
| 31 Mar 21 | 4,058 | 38 | 149 | 0 |
| 31 Dec 20 | 3,992 | 41 | 143 | 0 |
| 30 Sep 20 | 3,819 | 35 | 137 | 0 |
| 30 Jun 20 | 3,645 | 29 | 130 | 0 |
| 31 Mar 20 | 3,569 | 34 | 129 | 0 |
| 31 Dec 19 | 3,493 | 40 | 128 | 0 |
| 30 Sep 19 | 3,557 | 41 | 127 | 0 |
| 30 Jun 19 | 3,621 | 42 | 125 | 0 |
| 31 Mar 19 | 3,778 | 44 | 128 | 0 |
| 31 Dec 18 | 3,935 | 45 | 130 | 0 |
| 30 Sep 18 | 4,075 | 46 | 129 | 0 |
| 30 Jun 18 | 4,214 | 47 | 128 | 0 |
| 31 Mar 18 | 4,155 | 46 | 124 | 0 |
| 31 Dec 17 | 4,096 | 45 | 120 | 0 |
| 30 Sep 17 | 3,946 | 54 | 112 | 0 |
| 30 Jun 17 | 3,796 | 63 | 104 | 0 |
| 31 Mar 17 | 3,733 | 60 | 98 | 0 |
| 31 Dec 16 | 3,670 | 56 | 93 | 0 |
| 30 Sep 16 | 3,605 | 47 | 88 | 0 |
| 30 Jun 16 | 3,540 | 38 | 83 | 0 |
| 31 Mar 16 | 3,468 | 32 | 82 | 0 |
| 31 Dec 15 | 3,397 | 26 | 81 | 0 |
| 30 Sep 15 | 3,299 | 31 | 82 | 0 |
| 30 Jun 15 | 3,200 | 35 | 83 | 0 |
| 31 Mar 15 | 3,107 | 36 | 78 | 0 |
| 31 Dec 14 | 3,014 | 36 | 73 | 0 |
| 31 Dec 13 | 2,401 | 22 | 59 | 0 |
Des revenus de qualité: 2289 has high quality earnings.
Augmentation de la marge bénéficiaire: 2289's current net profit margins (1.2%) are lower than last year (2.2%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 2289's earnings have grown by 15.6% per year over the past 5 years.
Accélération de la croissance: 2289's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: 2289 had negative earnings growth (-43.2%) over the past year, making it difficult to compare to the Healthcare industry average (3.1%).
Rendement des fonds propres
ROE élevé: 2289's Return on Equity (8.6%) is considered low.